Comparison of the Effectiveness of Cromolyn Sodium Mometasone and Azelastine Nasal Sprays' in Improving Nasal Symptoms in Patients with Moderate to Severe Persistent Allergic Rhinitis.

Evaluation and comparison of the efficacy of Cromolyn sodium , Mometazone, and Azelastin in improving nasal symptoms in patients with moderate to severe persistent Allergic Rhinitis.

A Phase 2, randomized, double blind, parallel-group, controlled clinical trial involving 108 patients; Random Allocation software was used for randomization.

Patient symptoms are assessed and scored using the Total Nasal Symptom Score (TNSS). This questionnaire comprises four components nasal congestion, rhinorrhea, sneezing, and nasal itching each scored from 0 to 3 based on symptom severity, resulting in a total score ranging from 0 to 12. Patients will be evaluated on two occasions: day one (prior to initiating medication) and day twenty-eight (after starting medication); necessary information will be collected from the patients and recorded on data forms. Matching for age and sex will be performed, and the study will be conducted in a double-blind manner using identical spray containers prepared by a pharmacist and assigned to three groups ;ensuring that neither the administrator nor the patient is aware of the specific spray type. The study will be conducted at the Al-Zahra ENThospital in Zahedan.

Inclusion criteria: patients with a confirmed diagnosis of Allergic Rhinitis; age 18–50 years; moderate-to-severe Allergic Rhinitis based on symptom severity; and provision of written informed consent to participate in the study.

For Sodium Cromoglicate, the dosage is one spray in each nostril, four times daily; For Azelastin, is one spray in each nostril, twice daily; For Mometazone is one spray in each nostril, twice daily.

Recipients of mometasone spray in the control group are compared with recipients of azelastine and cromolyn sodium sprays regarding their response to treatment.

They are placed randomly in a block way (using Random Allocation software) in three equal spheres. With box unit.

A pharmacist has coded three spray medications—packaged in containers identical in color, shape, and volume as Code 1, Code 2, and Code 3, with each code corresponding to a specific drug. A clinical caregiver hands one of the coded sprays to each patient for use, while neither the patient nor the caregiver knows which drug corresponds to which code. Ultimately, following an analysis by the researchers, the specific drug associated with each code is revealed.

No information exist.